Author

Kei Irie

Cincinnati Children's Hospital Medical CenterORCID 0000-0001-9878-4672Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Brendan M. Boyle· 1 shared Jack ReifenbergiD· 1 shared Jeffrey S. HyamsiD· 1 shared Joshua D. NoeiD· 1 shared Phillip MinariD· 1 shared Tomoyuki MizunoiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Brendan M. Boyle

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintMay 1, 2025

Hybrid Population PK-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's Disease

Kei Irie, Phillip Minar, Jack Reifenberg…·Tomoyuki Mizuno

This paper develops a hybrid population PK-ML model to improve infliximab concentration predictions in pediatric and young adult Crohn's disease patients, showing better accuracy than Bayesian estimation alone.

DOI 10.1101/2025.05.01.651780

humanclinical cohort / trial

𝕏 PostBluesky